GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuCell Corp (NAS:ICCC) » Definitions » Shiller PE Ratio

ImmuCell (ImmuCell) Shiller PE Ratio : (As of Apr. 25, 2024)


View and export this data going back to 1995. Start your Free Trial

What is ImmuCell Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


ImmuCell Shiller PE Ratio Historical Data

The historical data trend for ImmuCell's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuCell Shiller PE Ratio Chart

ImmuCell Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ImmuCell Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ImmuCell's Shiller PE Ratio

For the Biotechnology subindustry, ImmuCell's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmuCell's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuCell's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ImmuCell's Shiller PE Ratio falls into.



ImmuCell Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

ImmuCell's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, ImmuCell's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.15/129.4194*129.4194
=-0.150

Current CPI (Dec. 2023) = 129.4194.

ImmuCell Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.004 99.695 -0.005
201406 -0.100 100.560 -0.129
201409 0.003 100.428 0.004
201412 0.040 99.070 0.052
201503 0.150 99.621 0.195
201506 0.030 100.684 0.039
201509 0.110 100.392 0.142
201512 0.090 99.792 0.117
201603 0.110 100.470 0.142
201606 -0.002 101.688 -0.003
201609 0.010 101.861 0.013
201612 0.000 101.863 0.000
201703 0.120 102.862 0.151
201706 -0.050 103.349 -0.063
201709 -0.070 104.136 -0.087
201712 -0.040 104.011 -0.050
201803 -0.040 105.290 -0.049
201806 -0.150 106.317 -0.183
201809 -0.050 106.507 -0.061
201812 -0.190 105.998 -0.232
201903 0.030 107.251 0.036
201906 -0.090 108.070 -0.108
201909 -0.070 108.329 -0.084
201912 -0.060 108.420 -0.072
202003 -0.020 108.902 -0.024
202006 -0.110 108.767 -0.131
202009 -0.040 109.815 -0.047
202012 0.030 109.897 0.035
202103 -0.060 111.754 -0.069
202106 0.020 114.631 0.023
202109 0.020 115.734 0.022
202112 0.010 117.630 0.011
202203 0.070 121.301 0.075
202206 -0.090 125.017 -0.093
202209 -0.080 125.227 -0.083
202212 -0.210 125.222 -0.217
202303 -0.300 127.348 -0.305
202306 -0.180 128.729 -0.181
202309 -0.120 129.860 -0.120
202312 -0.150 129.419 -0.150

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ImmuCell  (NAS:ICCC) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


ImmuCell Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of ImmuCell's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmuCell (ImmuCell) Business Description

Traded in Other Exchanges
Address
56 Evergreen Drive, Portland, ME, USA, 04103
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. It has two segments Scours and Mastitis. The company generates the majority of its revenue from the United States.
Executives
Bryan K. Gathagan director 56 EVERGREEN DRIVE, PORTLAND ME 04103
David Cunningham director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Gloria F Basse director 56 EVERGREEN DRIVE, PORTLAND ME 04103
David Scott Tomsche director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Steven T. Rosgen director C/O IMMUCELL CORPORATION, 56 EVERGREEN DR., PORTLAND ME 04103
Norman H Pessin other: See Explanation of Responses C/O LEVY, HARKINS & CO., INC., 366 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Brian L. Pessin other: See Explanation of Responses 310 EAST 75TH STREET, APT. 2A, NEW YORK NY 10021
Joseph H Crabb director, officer: Vice President and CSO IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Elizabeth Luttrell Williams officer: Vice Pres. of Mfg Operations C/O IMMUCELL CORPORATION, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Jonathan E Rothschild director, 10 percent owner C/O IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Linda Rhodes director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Paul R Wainman director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Michael F Brigham director, officer: President and CEO IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Bobbi Jo Kunde other: Director of Sales and Marketin 56 EVERGREEN DRIVE, PORTLAND ME 04103
Robert C Bruce director 56 EVERGREEN DRIVE, PORTLAND ME 04103